Related Experiment Video
Updated: Aug 14, 2025

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Novel Diarylthioether Compounds as Agents for the Treatment of Chagas Disease
Julia Beveridge1,2, Eric Tran1,2, Girdhar Singh Deora1,2
1Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Abstract:
Herein, we describe the hit optimization of a novel diarylthioether chemical class found to be active against Trypanosoma cruzi; the parasite responsible for Chagas disease. The hit compound was discovered through a whole-cell phenotypic screen and as such, the mechanism of action for this chemical class is unknown. Our investigations led to clear structure-activity relationships and the discovery of several analogues with high in vitro potency. Furthermore, we observed excellent activity during acute in vivo efficacy studies in mice infected with transgenic T. cruzi. These diarylthioether compounds represent a promising new chemotype for Chagas disease drug discovery and merit further development to increase oral exposure without increasing toxicity.
Related Concept Videos
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

